Poster 63 reports responses to #EnHERTu. Interesting that some responses seem much slower than I might have expected. This is really quite a nice poster and the outcome details will have taken some effort to get. I'm never satisfied! I'd have loved to see a swimmer plot and a waterfall plot here

#breastcancer #NICE #NHS #HEOR #Enhertu #AstraZeneca #DaiichiSankyo #Oncology #HER2lowbreastcancer #incurablebreastcancer #NICEFinaldraftguidance #reimbursement #metastaticbreastcancer #NICEcosteffectivenessthreshold #NICErecommendation #CancerDrugsFund #NHScommissioning
zurl.co/eYPtT

What is Enhertu and how could the new NHS breast cancer treatment help patients?

#Enhertu #BreastCancerTreatment #NHSHealthcare #CancerResearch #PatientSupport

www.easterneye.biz/enhertu-brea...

.
You can listen to Anita Rani's interview on #Enhertu finally being approved today with campaigner Sophie Blake who has stage 4 breast cancer and Dr Simon Vincent, Chief Scientific Officer at Breast Cancer Now here on BBC Sounds (20 minutes in):

#bbcpm #cancercare
.
www.bbc.co.uk/sounds/play/...

DESTINY-Lung04：#Enhertu 在1L HER2突变 #非小细胞肺癌 击败化疗+帕博利珠单抗。
• PFS: 14.3 vs 8.3月
• ORR: 70% vs 44.5%
• OS: 29.3 vs 33.1月

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #新闻 #媒体 #肺癌

DESTINY-Lung04: #Enhertu supera quimio+pembro em 1L #CPNPC HER2+
• SLP: 14,3 vs 8,3m
• TRO: 70% vs 44,5%
• SG: 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #notícias #mídia #CâncerDePulmão

DESTINY-Lung04: #Enhertu batte chemio+pembro in 1L #NSCLC HER2+ • PFS: 14,3 vs 8,3m • ORR: 70% vs 44,5% • OS: 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #notizie #media #TumoreAlPolmone

DESTINY-Lung04: #Enhertu schlägt Chemo+Pembro in 1L HER2+ #NSCLC
• PFS: 14,3 vs 8,3M
• ORR: 70% vs 44,5%
• OS: 29,3 vs 33,1M

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #Nachrichten #Medien #Lungenkrebs

DESTINY-Lung04 : #Enhertu bat chimio+pembro en 1L #CBNPC HER2+
• SSP : 14,3 vs 8,3m
• TRG : 70% vs 44,5%
• SG : 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #news #media #CancerDuPoumon #HER2

DESTINY-Lung04: #Enhertu supera quimio+pembro en 1L #CPNM HER2+
• SLP: 14,3 vs 8,3m
• TRO: 70% vs 44,5%
• SG: 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #news #media #CáncerDePulmón #HER2

The news that #enhertu is to be made available to #secondarybreastcancer patients in England is testimony to the unrelenting campaigning of the secondary breast cancer community alongside breast cancer charities including @make2ndscount.bsky.social . Well done to all involved.

Around 1,000 patients in #England with a form of incurable #breastcancer will be able to get access to #AstraZeneca and #DaiichiSankyo's life-extending drug, #Enhertu, via the #NHS from today.

pharmaphorum.com/news/nice-fi...

.
Brilliant news that breast cancer patients can now get #Enhertu on the NHS which will extend people's lives - thank you to all who have campaigned for it!

#r4today #bbcbreakfast #GMB #breastcancer
.
bsky.app/profile/brea...

NHS England approves life-extending breast cancer drug Enhertu after cost deal

🤖 IA: It's not clickbait ✅
👥 Users: It's not clickbait ✅

#breastcancer #nhs #enhertu

👇👇👇

HER2変異陽性肺がん1次治療のEnhertu第3相結果をAstraZenecaと第一三共が発表──無増悪生存期間と安全性
stellanews.life/technology/1... #DESTINY-Lung04 #Enhertu

Ph3 DESTINY-Lung04: #Enhertu erzielt 14,3 Mo. mPFS vs. 8,3 Mo. mit #Pembrolizumab + Chemo bei 1L HER2-mutiertem #NSCLC (37% geringeres Risiko Progress/Tod).
www.ipharmacenter.com/post/iaslc-2...
#WCLC2026 #WCLC26

DESTINY-Lung04 (Ph3) : #Enhertu atteint 14,3 m de SSP vs 8,3 m sous #pembrolizumab + chimio en 1L dans le #CPNPC muté HER2 (-37% risque décès/progression)
www.ipharmacenter.com/post/iaslc-2...
#WCLC2026 #WCLC26 #Oncologie

#Enhertu alcanzó 14,3 meses de mediana de SLP vs 8,3 meses con #pembrolizumab + quimio en 1L para #CPCNP con mutación HER2
www.ipharmacenter.com/post/iaslc-2...
#WCLC2026 #WCLC26 #Oncología

#AstraZeneca 's cancer pipeline posts two wins and a loss

#ENHERTU and #TAGRISSO Show Promise Despite #Etcamah Setbacks

www.clinicaltrialsarena.com/news/astraze...